Novo Nordisk
Våre danske venner får sperre øynene opp. Her kommer en artikkel som er sponset av Novo Nordisk og Lundbeck
https://www.tandfonline.com/doi/full/10.1080/19490976.2021.1900995
En multi-omics studie på antibiotika resistens.
Og ja, de bruker SAN til sånt 🤓
Fünke
08.01.2023 kl 20:24
975
https://www.pharmaceutical-technology.com/sponsored/enabling-the-next-wave-of-innovative-drug-therapies-with-speciality-enzymes/
Noen har snakket om dette tidligere. Muligens det var du Josef, men fint med en oppfriskning. Om noen ikke ser potensialet i hva AZT driver med, så gjør i alle fall Novo det. Det det pekes på i artikkelen er akkurat hva AZT leverer allerede.
Dette er vel det viktigste: « The impact could be huge for the biopharma industry. Superior specialty enzymes will help drive down manufacturing costs by increasing productivity and reducing the amount of raw materials needed. According to Laursen, raw materials currently contribute up to 50% of the costs of producing these advanced therapies.
As the industry defines higher quality and cost-effective processes for producing cell and gene therapies, enzymes will play a key role, helping companies deliver more accessible and affordable therapies to patients.»
Noen har snakket om dette tidligere. Muligens det var du Josef, men fint med en oppfriskning. Om noen ikke ser potensialet i hva AZT driver med, så gjør i alle fall Novo det. Det det pekes på i artikkelen er akkurat hva AZT leverer allerede.
Dette er vel det viktigste: « The impact could be huge for the biopharma industry. Superior specialty enzymes will help drive down manufacturing costs by increasing productivity and reducing the amount of raw materials needed. According to Laursen, raw materials currently contribute up to 50% of the costs of producing these advanced therapies.
As the industry defines higher quality and cost-effective processes for producing cell and gene therapies, enzymes will play a key role, helping companies deliver more accessible and affordable therapies to patients.»
Zleep
14.04.2021 kl 19:55
1861
Tror ikke Novofonden har ejerskab så havde det fremgået af listen her https://www.novoholdings.dk/investments/#show-more men spændende artikel alligevel. Virker til Morten Sommer har en fin succerate
Zleep
14.04.2021 kl 19:37
1904
Interessant CV At 35, Morten Sommer is not only the youngest full professor ever in Denmark but also the entrepreneur behind a number of synbio-based companies. For Labiotech’s second Hangout on June 29th, Philip probed his thoughts on academia, entrepreneurship and finding a way to balance tandem careers on these paths. While earning his PhD in George Church‘s lab at Harvard, Sommer co-founded his first company, Microlytic in 2006, which has since been acquired by Anatrace. He also co-founded two others, Antibiotix and Biosyntia
Zleep
14.04.2021 kl 17:45
2074
Tror det er dette firma som står bag https://www.sniprbiome.com som måske udvikler pencilins afløser. Morten O A Sommer er hovedforfatter på ovenstående artikl og sidder i bestyelsen i Sniprbiome som delvist er ejet af Lundbeckfonden. Men mon ikke Novo fonden også har en andel
https://finans.dk/tech/ECE11747931/flyttede-fra-england-til-danmark-snipr-biome-er-paa-vej-med-banebrydende-afloeser-for-penicillin/?ctxref=ext
SNIPR BIOME is a leading CRISPR and microbiome biotech company incorporated in Copenhagen, Denmark. SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based drugs deploying its proprietary and patentprotected CRISPR/Cas platform. SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient’s microbial community intact. In March 2019, SNIPR BIOME closed a $50 million Series A financing by Lundbeckfonden Emerge (Copenhagen), Life Sciences Partners (Amsterdam), North-East Family Office (Copenhagen) and Wellington Partners (Munich).
For more details, please visit: www.sniprbiome.com
https://finans.dk/tech/ECE11747931/flyttede-fra-england-til-danmark-snipr-biome-er-paa-vej-med-banebrydende-afloeser-for-penicillin/?ctxref=ext
SNIPR BIOME is a leading CRISPR and microbiome biotech company incorporated in Copenhagen, Denmark. SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based drugs deploying its proprietary and patentprotected CRISPR/Cas platform. SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient’s microbial community intact. In March 2019, SNIPR BIOME closed a $50 million Series A financing by Lundbeckfonden Emerge (Copenhagen), Life Sciences Partners (Amsterdam), North-East Family Office (Copenhagen) and Wellington Partners (Munich).
For more details, please visit: www.sniprbiome.com
Zleep
14.04.2021 kl 16:06
2218
Det er Novo fonden og ikke Novo Nordisk. Der er en væsentlig forskel. Når det er sagt så er teamet Lundbeck fonden og Novo fonden vist sig tidligere, at være en succes. Tænker her på Veloxis som var samme fonde der stod bag og som i øvrigt var min anden bedste investering efter AZT
Ja, det fik min danske opmærksomhed.
Alt, hvad Novo Nordisk rører ved, bliver som regel til guld.
Alt, hvad Novo Nordisk rører ved, bliver som regel til guld.
Redigert 14.04.2021 kl 14:57
Du må logge inn for å svare